Los Angeles - 
(NewMediaWire) - June 02, 2021 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against Provention
Bio, Inc. (“Provention” or “the Company”) (NASDAQ: PRVB) for
violations of §§10(b)
and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
Investors who
purchased the Company's securities between November 2, 2020 and April 8, 2021,
inclusive (the ''Class Period''), are encouraged to contact the firm before July
20, 2021.
If you are a
shareholder who suffered a loss, click here to participate.
We also encourage you
to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite
2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of
charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this
case, has not yet been certified, and until certification occurs, you are not
represented by an attorney. If you choose to take no action, you can remain an
absent class member.
According to the
Complaint, the Company made false and misleading statements to the market.
Provention’s Biologics License Application (“BLA”) for teplizumab was deficient
and would require additional submitted data to secure FDA approval. The
teplizumab BLA lacked the strong evidence and support that the Company led the
market to believe it had. The Company overstated the chances of the teplizumab
BLA being approved and its commercial timeline. Based on these facts, the
Company’s public statements were false and materially misleading throughout the
class period. When the market learned the truth about Provention, investors
suffered damages.
Join the case to recover your losses.
The Schall Law Firm
represents investors around the world and specializes in securities class
action lawsuits and shareholder rights litigation.
This press release may
be considered Attorney Advertising in some jurisdictions under the applicable
law and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm
